We are live on ! Find out more
SPRY icon

ARS Pharmaceuticals
SPRY

188 hedge funds and large institutions have $840M invested in ARS Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 69 increasing their positions, 44 reducing their positions, and 42 closing their positions.

New
Increased
Maintained
Reduced
Closed

81% more call options, than puts

Call options by funds: $13.5M | Put options by funds: $7.46M

57% more repeat investments, than reductions

Existing positions increased: 69 | Existing positions reduced: 44

2% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 42

1% more funds holding

Funds holding: 187 → 188 (+1)

1.43% less ownership

Funds ownership: 86.06% → 84.63% (-1.4%)

43% less capital invested

Capital invested by funds: $1.48B → $840M (-$635M)

88% less funds holding in top 10

Funds holding in top 10: 8 → 1 (-7)

Holders
188
Holders Change
+1
Holders Change %
+0.53%
% of All Funds
2.47%
Holding in Top 10
1
Holding in Top 10 Change
-7
Holding in Top 10 Change %
-87.5%
% of All Funds
0.01%
New
43
Increased
69
Reduced
44
Closed
42
Calls
$13.5M
Puts
$7.46M
Net Calls
+$6.02M
Net Calls Change
-$1.06M

Top Buyers

Rank Fund Capital Flow
1
RCMNY
Rubric Capital Management (New York)
New York
+$46M
2
CC
Casdin Capital
New York
+$23M
3
Aberdeen Group
Aberdeen Group
United Kingdom
+$22.9M
4
BAMCO Inc
BAMCO Inc
New York
+$17.6M
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$14.9M

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$31.9M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$30.2M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$25M
4
OCA
Octagon Capital Advisors
New York
-$23.6M
5
CAM
Cormorant Asset Management
Massachusetts
-$19.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
N
51
Nuveen
North Carolina
$1.5M +$150K +10,464 +8%
HSA
52
Hussman Strategic Advisors
Maryland
$1.48M +$603K +42,000 +40%
SPIA
53
Steward Partners Investment Advisory
New York
$1.47M +$266K +18,512 +14%
XT
54
XTX Topco
Cayman Islands
$1.44M +$1.82M +126,543 +740%
DCM
55
DAFNA Capital Management
California
$1.41M +$2.02M +140,500 New
KOCAA
56
Knights of Columbus Asset Advisors
Connecticut
$1.35M +$953K +66,382 +97%
QOP
57
Quinn Opportunity Partners
Virginia
$1.26M +$1.15M +80,000 +178%
Rafferty Asset Management
58
Rafferty Asset Management
New York
$1.23M +$597K +41,564 +51%
VOYA Investment Management
59
VOYA Investment Management
Georgia
$1.15M -$737K -51,331 -31%
ACM
60
Aquatic Capital Management
Illinois
$1.06M +$819K +57,063 +117%
CBA
61
Coastal Bridge Advisors
Connecticut
$921K +$66.7K +4,650 +5%
EIP
62
Epoch Investment Partners
New York
$904K +$247K +17,200 +24%
Cambridge Investment Research Advisors
63
Cambridge Investment Research Advisors
Iowa
$876K -$14 -1 -0%
Swiss National Bank
64
Swiss National Bank
Switzerland
$847K – – –
VFIC
65
Valley Forge Investment Consultants
Pennsylvania
$836K – – –
SAM
66
Sectoral Asset Management
Quebec, Canada
$822K +$230K +16,000 +24%
RhumbLine Advisers
67
RhumbLine Advisers
Massachusetts
$816K -$818 -57 -0.1%
SC
68
Sculptor Capital
New York
$775K +$1.11M +77,100 New
Principal Financial Group
69
Principal Financial Group
Iowa
$773K +$308K +21,438 +39%
SIA
70
Sit Investment Associates
Minnesota
$749K +$490K +34,175 +85%
Wells Fargo
71
Wells Fargo
California
$742K +$183K +12,736 +21%
Two Sigma Investments
72
Two Sigma Investments
New York
$725K +$1.04M +72,177 New
BHCM
73
Brevan Howard Capital Management
Jersey
$675K +$965K +67,212 New
CM
74
CastleKnight Management
New York
$656K – – –
CCIA
75
Campbell & Co Investment Adviser
Maryland
$608K +$869K +60,525 New
1 2
3
4 5

SPRY Hedge Fund Activity: Q3 2025 in Review

188 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q3 2025, worth a combined $840M — down 43% from $1.48B a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new SPRY positions and 42 closed out — a net gain of 1 holder — while 69 added to existing stakes and 44 trimmed.

The largest buyer was Rubric Capital Management (New York), adding an estimated $46M. The largest seller was Deerfield Management, cutting an estimated $31.9M.

  • 188 institutional investors held ARS Pharmaceuticals (SPRY) as of Q3 2025, up from 187 in Q2 2025.
  • Funds reported $840M of ARS Pharmaceuticals stock for Q3 2025, down 43% quarter-over-quarter.
  • 43 funds opened new ARS Pharmaceuticals positions in Q3 2025 and 42 closed out, a net change of +1 holder.
  • The largest ARS Pharmaceuticals buyer in Q3 2025 was Rubric Capital Management (New York), an estimated $46M added.
  • The largest ARS Pharmaceuticals seller in Q3 2025 was Deerfield Management, an estimated $31.9M sold.

Based on aggregated 13F filings for Q3 2025.